Create a narrative

ANI Pharmaceuticals Community

NasdaqGM:ANIP Community

1 Narratives written by author
0 Comments on narratives written by author
2 Fair Values set on narratives written by author

ANI Pharmaceuticals

AN

AnalystConsensusTarget

AnalystConsensusTarget

Consensus Narrative from 8 Analysts

Expanding ACTH Potential And Rare Disease Markets Will Evolve

Key Takeaways Multiyear revenue growth is driven by expanding Cortrophin Gel potential, new product launches, and increasing adoption among previously untapped prescribers. Strategic investments in U.S. manufacturing, rare diseases, and complex generics strengthen margins, diversify the portfolio, and support resilience against supply chain and regulatory risks.

US$90.50

FV

0.6% undervalued

9.58%

Revenue growth p.a.

0

0

1

Updated